Panacea Index Logo

Command Palette

Search for a command to run...

Adverse events of iron and/or erythropoiesis-stimulating agent therapy in preoperatively anemic elective surgery patients: a systematic review.

Systematic reviews
January 1, 1970
Jorien Laermans et al. (11 authors)
Journal ArticleSystematic ReviewResearch Support, Non-U.S. Gov'tHuman Study
Study Details

Study Goal

The researchers aimed to investigate the occurrence of adverse events associated with erythropoiesis-stimulating agents (ESAs) and iron therapy in preoperative anemia treatment.

Results Summary

The study found very low certainty evidence regarding the safety of ESA and/or iron therapy, with most adverse event data focusing on mortality, thromboembolic, infectious, cardiovascular, and gastrointestinal events. The high risk of bias and limitations in study design, data collection, and reporting contributed to the uncertainty.

Population

Adult elective surgery patients with preoperative anemia.

Effective Dosage

Not specified

Duration

Not specified

Interactions

None mentioned

Extracted Claims (19)
InterventionDirectionEndpointPopulationDosageImpactClaim #
iron supplementation
neutral
preoperative anemia treatment
patients with preoperative anemia
-
hallmark therapy
#1
erythropoiesis-stimulating agent (ESA) administration
neutral
preoperative anemia treatment
patients with preoperative anemia
-
hallmark therapy
#2
intravenous (IV) iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#3
oral iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#4
IV iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#5
usual care/no iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#6
IV ferric carboxymaltose
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#7
IV iron sucrose
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#8
ESA+iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#9
control (placebo and/or iron, no treatment)
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#10
ESA+IV iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#11
ESA+oral iron
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#12
ESA+IV iron (different ESA dosing regimens)
neutral
adverse events
adult elective surgery patients with preoperative anemia
-
compared to
#13
iron and/or ESAs
neutral
mortality/survival adverse events
adult elective surgery patients with preoperative anemia
-
investigated
#14
iron and/or ESAs
neutral
thromboembolic adverse events
adult elective surgery patients with preoperative anemia
-
investigated
#15
iron and/or ESAs
neutral
infectious adverse events
adult elective surgery patients with preoperative anemia
-
investigated
#16
iron and/or ESAs
neutral
cardiovascular adverse events
adult elective surgery patients with preoperative anemia
-
investigated
#17
iron and/or ESAs
neutral
gastrointestinal adverse events
adult elective surgery patients with preoperative anemia
-
investigated
#18
ESA and/or iron therapy
no change
adverse events
preoperatively anemic elective surgery patients
-
remains unclear if associated with
#19
Abstract

BACKGROUND: Iron supplementation and erythropoiesis-stimulating agent (ESA) administration represent the hallmark therapies in preoperative anemia treatment, as reflected in a set of evidence-based treatment recommendations made during the 2018 International Consensus Conference on Patient Blood Management. However, little is known about the safety of these therapies. This systematic review investigated the occurrence of adverse events (AEs) during or after treatment with iron and/or ESAs. METHODS: Five databases (The Cochrane Library, MEDLINE, Embase, Transfusion Evidence Library, Web of Science) and two trial registries (ClinicalTrials.gov, WHO ICTRP) were searched until 23 May 2022. Randomized controlled trials (RCTs), cohort, and case-control studies investigating any AE during or after iron and/or ESA administration in adult elective surgery patients with preoperative anemia were eligible for inclusion and judged using the Cochrane Risk of Bias tools. The GRADE approach was used to assess the overall certainty of evidence. RESULTS: Data from 26 RCTs and 16 cohort studies involving a total of 6062 patients were extracted, on 6 treatment comparisons: (1) intravenous (IV) versus oral iron, (2) IV iron versus usual care/no iron, (3) IV ferric carboxymaltose versus IV iron sucrose, (4) ESA+iron versus control (placebo and/or iron, no treatment), (5) ESA+IV iron versus ESA+oral iron, and (6) ESA+IV iron versus ESA+IV iron (different ESA dosing regimens). Most AE data concerned mortality/survival (n=24 studies), thromboembolic (n=22), infectious (n=20), cardiovascular (n=19) and gastrointestinal (n=14) AEs. Very low certainty evidence was assigned to all but one outcome category. This uncertainty results from both the low quantity and quality of AE data due to the high risk of bias caused by limitations in the study design, data collection, and reporting. CONCLUSIONS: It remains unclear if ESA and/or iron therapy is associated with AEs in preoperatively anemic elective surgery patients. Future trial investigators should pay more attention to the systematic collection, measurement, documentation, and reporting of AE data.

Medical Subject Headings (MeSH)
AdultAnemiaElective Surgical ProceduresErythropoiesisFerric Oxide, SaccharatedHematinicsHumans
Study Links
Quality Scores
Safety30
Efficacy50/10
Quality60/10
Citation Metrics
Total Citations4
Citations/Year1.3
Relative Citation Ratio0.80
NIH Percentile42.1%
Research Impact Scores
APT Score0.50
Weight Score0.66
Normalized Score0.44